SCHEMBL4829720

SCHEMBL4829720

COC(=O)[C@H](Cc1ccc(-c2ccc(F)cc2)cc1)NC(=O)c1cc2ccccc2cc1O

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.56
HDAC1 Q13547 6/20 0.52
HDAC6 Q9UBN7 6/20 0.52
CDK2 P24941 2/20 0.52
TACR3 P29371 1/20 0.51
NOS2 P35228 3/20 0.48
NOS3 P29474 2/20 0.48
NOS1 P29475 2/20 0.48
ELANE P08246 2/20 0.48
TSHR P16473 1/20 0.47
KDM4E B2RXH2 1/20 0.46
ALDH1A1 P00352 1/20 0.46
PKM P14618 1/20 0.46
CA12 O43570 1/20 0.46
CA7 P43166 1/20 0.46
CA9 Q16790 1/20 0.46
CA14 Q9ULX7 1/20 0.46
GPR34 Q9UPC5 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4829713 1.00 KDR (0.56) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4831600 0.94 KDR (0.54) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4831594 0.94 KDR (0.54) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL13986736 0.93 KDR (0.60) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4824089 0.93 KDR (0.60) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4824091 0.93 KDR (0.60) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4824863 0.91 KDR (0.53) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4824854 0.91 KDR (0.53) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4827846 0.90 HDAC1 (0.63) KDRHDAC1HDAC6CDK2TACR3
SCHEMBL4827850 0.90 HDAC1 (0.63) KDRHDAC1HDAC6CDK2TACR3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7459472-B2 Aryl and heteroaryl compounds, compositions, and methods of use TRANSTECH PHARMA, INC. (US) 2008-12-02 US disclosed
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use VTVX HOLDINGS I LLC 2005-03-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050059713-A1 Aryl and heteroaryl compounds, compositions, and methods of use CYP2F1, CYP3A43, PNPO KDR 1624/4885HDAC1 1171/4885HDAC6 1063/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.